MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program
June 09, 2021 at 06:00 am EDT
MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. announced clinical data from a Phase 1b study of zandelisib, an investigational selective phosphatidylinositol 3-kinase delta ("PI3K") inhibitor in clinical development for the treatment of B-cell malignancies, and the trial design of COASTAL, a Phase 3 study of zandelisib in combination with rituximab, will be highlighted in poster presentations at the 16thInternational Conference on Malignant Lymphoma (16-ICML) to be held June 18 – 22, 2021. Details on the two e-poster presentations are included below: Title: Zandelisib, a PI3Kd Inhibitor on Intermittent Schedule (IS) in Follicular Lymphoma Patients who Progressed within 24 Months of First-Line Chemoimmunotherapy (POD24); Authors: John Pagel, et. al.; Abstract ID: 113. Title: COASTAL: A Phase 3 Study of the PI3Kd Inhibitor Zandelisib with Rituximab (R) versus Immunochemotherapy in Patients with Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma (iNHL); Authors: Wojciech Jurczak, et. al.; Abstract ID: 262.